Navigation Links
ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
Date:10/27/2011

ddress until November 18, 2011.

About ViroPharma Incorporated ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options, including C1 esterase inhibitor deficiency, treatment of seizures in children and adolescents, Friedreich's Ataxia (FA), adrenal insufficiency and C. difficile infection (CDI).  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve.  ViroPharma's commercial products address diseases including hereditary angioedema (HAE) and CDI; for full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Disclosure Notice Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2011, our ability to successfully commercialize Cinryze and Buccolam in the EU, our ability to complete manufa
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
2. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
3. ViroPharma Announces Additional Securities Repurchase Program
4. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
5. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
6. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
7. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
8. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
9. ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference
10. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
11. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Novastem, a ... its first patient in its study for ischemic ... American Stroke Association, ischemic strokes account for 87 ... enroll qualified patients in the study, entitled "Internal ... of Allogeneic Mesenchymal Stem Cells and Intrathecal Administration ...
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today that on December 24, 2014 ... The Company raised approximately $2.3 million ... to use the net proceeds from the offering ...
(Date:12/24/2014)... and LONDON , December 24, ... industry are expected to grow at an average rate ... of value and volume. Hip, knee and spine surgeries ... while in emerging economies they have a lower penetration. ... challenging the use of composites. Non-metallic orthopedic devices have ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... and INDIANAPOLIS , March 15 ... evaluated response rates in patients with a common genetic ... TRITON-TIMI 38 study were treated with dual antiplatelet therapy ... plus aspirin and managed with percutaneous coronary intervention (PCI) ...
... March 15 At this year,s annual meeting ... 14-16 in Atlanta , Royal Philips Electronics ... simplifying cardiology patient care by highlighting a range of ... tools, intuitive information management systems, new temperature modulation therapies, ...
Cached Medicine Technology:New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 2New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 3New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 4New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 5New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 6New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 7New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 8New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 9New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 10New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 11Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 2Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 3Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 4Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 5Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 6Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 7Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 8Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 9
(Date:12/25/2014)... BellasDress has launched its Christmas Sale, offering ... chosen their best-selling lace wedding dresses, vintage bridesmaid dresses ... , Now, BellasDress.com features popular women’s dresses, and ... prices. The business hopes everyone can have a memorable ... “All our elegant products are made with exquisite materials; ...
(Date:12/25/2014)... By Dennis Thompson ... -- Very sick children with complex chronic illnesses can receive ... a "medical home," with easy access to a team of ... were less likely to become seriously ill and need either ... received treatment at an enhanced medical home clinic at the ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience ... business has introduced its new collection of 2015 prom ... The new prom outfits are guaranteed to contain the ... are specially designed for 2015. Anyone who wants to ... its website before Jan. 26, 2015, the deadline of ...
(Date:12/25/2014)... December 25, 2014 Each year trauma ... 2 million hospital admissions across the nation (according to ... The CDC’s National Hospital Ambulatory Medical Care Survey ... survey conducted in 2010. They estimated that there were ... resulted in a primary diagnosis of broken bone or ...
(Date:12/24/2014)... Connie Casad, MD, a well-known and respected gynecologist, ... years of practice experience in Dallas, Texas, has announced ... dietary detoxification. The second study is scheduled to begin ... test patients who just completed a 21-day detoxification regimen. ... conducting the study, Dr. Casad said, "About 10 years ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3
... change when clocks are adjusted , , WEDNESDAY, Oct. 29 (HealthDay ... about here, and it may pose problems more serious than ... in the number of heart attacks following the semi-annual one-hour ... "This was the very first study on this topic and ...
... ORCH ), a leading worldwide provider of identity DNA ... of,2008., Total revenues were $14.9 million for the third ... of 2007. The decrease in,total revenues for the third quarter ... lower revenues in the U.K., Total U.S.-based revenues rose ...
... EPS Outlook and Announces 2009 Operating Preview, ... (Nasdaq: GTIV ), a leading provider of ... led by 17% revenue,growth and 26% operating contribution ... continued to invest in clinical innovation, quality and,productivity ...
... Get Annual Foot Check-ups, BETHESDA, Md., Oct. 30 ... and its complications every year.,However, medical care for diabetes ... according to a recent survey by the American Podiatric,Medical ... independent research firm, found that,25 percent of the 600 ...
... and Healthcare Interface Solutions Team to Integrate Innovative Web-based Referral ... , ... Atlanta, Ga. (PRWEB) October 30, ... Web-based admissions and referral automation software for hospitals and long-term ...
... by process industries and manufacturers of industrial machinery, growing demand for ... the growth in smart sensors market. Global market for Smart Sensors ... ... San Jose, CA (PRWEB) October 30, 2008 -- Sensor networks ...
Cached Medicine News:Health News:Semi-Annual Time Changes May Affect the Heart 2Health News:Semi-Annual Time Changes May Affect the Heart 3Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 2Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 3Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 4Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 5Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 6Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 7Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 8Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 2Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 3Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 4Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 5Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 6Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 7Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 8Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 9Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 10Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 11Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 12Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 13Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 14Health News:Study Finds Preventative Diabetes Care Reduces Amputation Occurrence 2Health News:Patient Placement Systems Selects Iatric Systems, Inc. to Deliver Interfaces for MEDITECH Healthcare Information Systems 2Health News:Patient Placement Systems Selects Iatric Systems, Inc. to Deliver Interfaces for MEDITECH Healthcare Information Systems 3Health News:Global Market for Smart Sensors to Reach $7.8 Billion by 2015, According to a New Report by Global Industry Analysts, Inc. 2Health News:Global Market for Smart Sensors to Reach $7.8 Billion by 2015, According to a New Report by Global Industry Analysts, Inc. 3
... Comet XL is a complete EEG system ... physician's office, hospital, or medical center. Ready ... the latest high performance PC and Photic ... and monitor sizes to suit your individual ...
... system is made up of our SleepWorks software ... perfect solution to your diagnostic sleep-testing needs. It's ... of this is backed up by 24/7 support ... professionals. Not only that, you can expand your ...
Aurora is a powerful Windows-based digital PSG instrument providing complete data acquisition, recording and review capabilities in one flexible package. The Aurora offers the most feature-packed PSG...
... purpose stimulator intended for nerve and muscle ... cell to entire muscle stimulation. It can ... pulses, trains of pulses and trains of ... include computer compatibility and flexibility of synchronization ...
Medicine Products: